StreetInsider.com News Articles

Roche Holding (ROG:SW) (RHHBY) PT Lowered to CHF325 at JPMorgan

Thu, 12 Mar 2026 04:05:43 -0400

JPMorgan analyst Richard Vosser lowered the price target on Roche Holding (ROG:SW) (OTC: RHHBY) to CHF325.00 (from CHF350.00) while maintaining a Neutral rating.

Roche Holding (ROG:SW) (RHHBY) PT Lowered to CHF325 at JPMorgan

Thu, 12 Mar 2026 04:05:43 -0400

JPMorgan analyst Richard Vosser lowered the price target on Roche Holding (ROG:SW) (OTC: RHHBY) to CHF325.00 (from CHF350.00) while maintaining a Neutral rating.

Roche Holding (ROG:SW) (RHHBY) PT Lowered to CHF325 at JPMorgan

Thu, 12 Mar 2026 04:05:43 -0400

JPMorgan analyst Richard Vosser lowered the price target on Roche Holding (ROG:SW) (OTC: RHHBY) to CHF325.00 (from CHF350.00) while maintaining a Neutral rating.

Roche Holding (ROG:SW) (RHHBY) PT Lowered to CHF325 at JPMorgan

Thu, 12 Mar 2026 04:05:43 -0400

JPMorgan analyst Richard Vosser lowered the price target on Roche Holding (ROG:SW) (OTC: RHHBY) to CHF325.00 (from CHF350.00) while maintaining a Neutral rating.

Genentech Provides Update on Phase III persevERA Study in ER-positive Advanced Breast Cancer

Mon, 09 Mar 2026 02:10:00 -0400

persevERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-free survival, but a numerical improvement was observed

Giredestrant plus palbociclib was well tolerated and adverse events were consistent with the known safety profiles of each individual treatment

Genentech is committed to transforming ER-positive breast cancer care, anchored by the landmark success of lidERA in early-stage disease and evERA in the advanced setting

The FDA recently accepted the New Drug Application based on evERA data; Phase III lidERA data will be submitted to the FDA in the coming weeks

persevERA is the first

Genentech Provides Update on Phase III persevERA Study in ER-positive Advanced Breast Cancer

Mon, 09 Mar 2026 02:10:00 -0400

persevERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-free survival, but a numerical improvement was observed

Giredestrant plus palbociclib was well tolerated and adverse events were consistent with the known safety profiles of each individual treatment

Genentech is committed to transforming ER-positive breast cancer care, anchored by the landmark success of lidERA in early-stage disease and evERA in the advanced setting

The FDA recently accepted the New Drug Application based on evERA data; Phase III lidERA data will be submitted to the FDA in the coming weeks

persevERA is the first

Genentech Provides Update on Phase III persevERA Study in ER-positive Advanced Breast Cancer

Mon, 09 Mar 2026 02:10:00 -0400

persevERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-free survival, but a numerical improvement was observed

Giredestrant plus palbociclib was well tolerated and adverse events were consistent with the known safety profiles of each individual treatment

Genentech is committed to transforming ER-positive breast cancer care, anchored by the landmark success of lidERA in early-stage disease and evERA in the advanced setting

The FDA recently accepted the New Drug Application based on evERA data; Phase III lidERA data will be submitted to the FDA in the coming weeks

persevERA is the first

Genentech Provides Update on Phase III persevERA Study in ER-positive Advanced Breast Cancer

Mon, 09 Mar 2026 02:10:00 -0400

persevERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-free survival, but a numerical improvement was observed

Giredestrant plus palbociclib was well tolerated and adverse events were consistent with the known safety profiles of each individual treatment

Genentech is committed to transforming ER-positive breast cancer care, anchored by the landmark success of lidERA in early-stage disease and evERA in the advanced setting

The FDA recently accepted the New Drug Application based on evERA data; Phase III lidERA data will be submitted to the FDA in the coming weeks

persevERA is the first

Genentech Provides Update on Phase III persevERA Study in ER-positive Advanced Breast Cancer

Mon, 09 Mar 2026 02:10:00 -0400

persevERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-free survival, but a numerical improvement was observed

Giredestrant plus palbociclib was well tolerated and adverse events were consistent with the known safety profiles of each individual treatment

Genentech is committed to transforming ER-positive breast cancer care, anchored by the landmark success of lidERA in early-stage disease and evERA in the advanced setting

The FDA recently accepted the New Drug Application based on evERA data; Phase III lidERA data will be submitted to the FDA in the coming weeks

persevERA is the first

Genentech Provides Update on Phase III persevERA Study in ER-positive Advanced Breast Cancer

Mon, 09 Mar 2026 02:10:00 -0400

persevERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-free survival, but a numerical improvement was observed

Giredestrant plus palbociclib was well tolerated and adverse events were consistent with the known safety profiles of each individual treatment

Genentech is committed to transforming ER-positive breast cancer care, anchored by the landmark success of lidERA in early-stage disease and evERA in the advanced setting

The FDA recently accepted the New Drug Application based on evERA data; Phase III lidERA data will be submitted to the FDA in the coming weeks

persevERA is the first

Genentech Provides Update on Phase III persevERA Study in ER-positive Advanced Breast Cancer

Mon, 09 Mar 2026 02:10:00 -0400

persevERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-free survival, but a numerical improvement was observed

Giredestrant plus palbociclib was well tolerated and adverse events were consistent with the known safety profiles of each individual treatment

Genentech is committed to transforming ER-positive breast cancer care, anchored by the landmark success of lidERA in early-stage disease and evERA in the advanced setting

The FDA recently accepted the New Drug Application based on evERA data; Phase III lidERA data will be submitted to the FDA in the coming weeks

persevERA is the first

Genentech Provides Update on Phase III persevERA Study in ER-positive Advanced Breast Cancer

Mon, 09 Mar 2026 02:10:00 -0400

persevERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-free survival, but a numerical improvement was observed

Giredestrant plus palbociclib was well tolerated and adverse events were consistent with the known safety profiles of each individual treatment

Genentech is committed to transforming ER-positive breast cancer care, anchored by the landmark success of lidERA in early-stage disease and evERA in the advanced setting

The FDA recently accepted the New Drug Application based on evERA data; Phase III lidERA data will be submitted to the FDA in the coming weeks

persevERA is the first

Genentech Provides Update on Phase III persevERA Study in ER-positive Advanced Breast Cancer

Mon, 09 Mar 2026 02:10:00 -0400

persevERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-free survival, but a numerical improvement was observed

Giredestrant plus palbociclib was well tolerated and adverse events were consistent with the known safety profiles of each individual treatment

Genentech is committed to transforming ER-positive breast cancer care, anchored by the landmark success of lidERA in early-stage disease and evERA in the advanced setting

The FDA recently accepted the New Drug Application based on evERA data; Phase III lidERA data will be submitted to the FDA in the coming weeks

persevERA is the first

Genentech Provides Update on Phase III persevERA Study in ER-positive Advanced Breast Cancer

Mon, 09 Mar 2026 02:10:00 -0400

persevERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-free survival, but a numerical improvement was observed

Giredestrant plus palbociclib was well tolerated and adverse events were consistent with the known safety profiles of each individual treatment

Genentech is committed to transforming ER-positive breast cancer care, anchored by the landmark success of lidERA in early-stage disease and evERA in the advanced setting

The FDA recently accepted the New Drug Application based on evERA data; Phase III lidERA data will be submitted to the FDA in the coming weeks

persevERA is the first

Genentech Provides Update on Phase III persevERA Study in ER-positive Advanced Breast Cancer

Mon, 09 Mar 2026 02:10:00 -0400

persevERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-free survival, but a numerical improvement was observed

Giredestrant plus palbociclib was well tolerated and adverse events were consistent with the known safety profiles of each individual treatment

Genentech is committed to transforming ER-positive breast cancer care, anchored by the landmark success of lidERA in early-stage disease and evERA in the advanced setting

The FDA recently accepted the New Drug Application based on evERA data; Phase III lidERA data will be submitted to the FDA in the coming weeks

persevERA is the first

Genentech Provides Update on Phase III persevERA Study in ER-positive Advanced Breast Cancer

Mon, 09 Mar 2026 02:10:00 -0400

persevERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-free survival, but a numerical improvement was observed

Giredestrant plus palbociclib was well tolerated and adverse events were consistent with the known safety profiles of each individual treatment

Genentech is committed to transforming ER-positive breast cancer care, anchored by the landmark success of lidERA in early-stage disease and evERA in the advanced setting

The FDA recently accepted the New Drug Application based on evERA data; Phase III lidERA data will be submitted to the FDA in the coming weeks

persevERA is the first

New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Genentech’s Gazyva Significantly Reduces Disease Activity in the Most Common Form of Lupus

Fri, 06 Mar 2026 08:45:00 -0400

Over three quarters of people on Gazyva plus standard therapy achieved at least a four-point improvement in SRI-4, a measure that assesses disease severity and symptoms
Gazyva has the potential to become a new standard of care for people living with systemic lupus erythematosus (SLE)
If approved, Gazyva would be the first Type II anti-CD20 therapy for SLE to directly target B cells, a key driver of inflammation and disease activity
SLE is a potentially life-threatening autoimmune disease that affects more than three million people worldwide

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO,

New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Genentech’s Gazyva Significantly Reduces Disease Activity in the Most Common Form of Lupus

Fri, 06 Mar 2026 08:45:00 -0400

Over three quarters of people on Gazyva plus standard therapy achieved at least a four-point improvement in SRI-4, a measure that assesses disease severity and symptoms
Gazyva has the potential to become a new standard of care for people living with systemic lupus erythematosus (SLE)
If approved, Gazyva would be the first Type II anti-CD20 therapy for SLE to directly target B cells, a key driver of inflammation and disease activity
SLE is a potentially life-threatening autoimmune disease that affects more than three million people worldwide

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO,

New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Genentech’s Gazyva Significantly Reduces Disease Activity in the Most Common Form of Lupus

Fri, 06 Mar 2026 08:45:00 -0400

Over three quarters of people on Gazyva plus standard therapy achieved at least a four-point improvement in SRI-4, a measure that assesses disease severity and symptoms
Gazyva has the potential to become a new standard of care for people living with systemic lupus erythematosus (SLE)
If approved, Gazyva would be the first Type II anti-CD20 therapy for SLE to directly target B cells, a key driver of inflammation and disease activity
SLE is a potentially life-threatening autoimmune disease that affects more than three million people worldwide

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO,

New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Genentech’s Gazyva Significantly Reduces Disease Activity in the Most Common Form of Lupus

Fri, 06 Mar 2026 08:45:00 -0400

Over three quarters of people on Gazyva plus standard therapy achieved at least a four-point improvement in SRI-4, a measure that assesses disease severity and symptoms
Gazyva has the potential to become a new standard of care for people living with systemic lupus erythematosus (SLE)
If approved, Gazyva would be the first Type II anti-CD20 therapy for SLE to directly target B cells, a key driver of inflammation and disease activity
SLE is a potentially life-threatening autoimmune disease that affects more than three million people worldwide

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO,

New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Genentech’s Gazyva Significantly Reduces Disease Activity in the Most Common Form of Lupus

Fri, 06 Mar 2026 08:45:00 -0400

Over three quarters of people on Gazyva plus standard therapy achieved at least a four-point improvement in SRI-4, a measure that assesses disease severity and symptoms
Gazyva has the potential to become a new standard of care for people living with systemic lupus erythematosus (SLE)
If approved, Gazyva would be the first Type II anti-CD20 therapy for SLE to directly target B cells, a key driver of inflammation and disease activity
SLE is a potentially life-threatening autoimmune disease that affects more than three million people worldwide

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO,

New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Genentech’s Gazyva Significantly Reduces Disease Activity in the Most Common Form of Lupus

Fri, 06 Mar 2026 08:45:00 -0400

Over three quarters of people on Gazyva plus standard therapy achieved at least a four-point improvement in SRI-4, a measure that assesses disease severity and symptoms
Gazyva has the potential to become a new standard of care for people living with systemic lupus erythematosus (SLE)
If approved, Gazyva would be the first Type II anti-CD20 therapy for SLE to directly target B cells, a key driver of inflammation and disease activity
SLE is a potentially life-threatening autoimmune disease that affects more than three million people worldwide

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO,

New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Genentech’s Gazyva Significantly Reduces Disease Activity in the Most Common Form of Lupus

Fri, 06 Mar 2026 08:45:00 -0400

Over three quarters of people on Gazyva plus standard therapy achieved at least a four-point improvement in SRI-4, a measure that assesses disease severity and symptoms
Gazyva has the potential to become a new standard of care for people living with systemic lupus erythematosus (SLE)
If approved, Gazyva would be the first Type II anti-CD20 therapy for SLE to directly target B cells, a key driver of inflammation and disease activity
SLE is a potentially life-threatening autoimmune disease that affects more than three million people worldwide

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO,

New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Genentech’s Gazyva Significantly Reduces Disease Activity in the Most Common Form of Lupus

Fri, 06 Mar 2026 08:45:00 -0400

Over three quarters of people on Gazyva plus standard therapy achieved at least a four-point improvement in SRI-4, a measure that assesses disease severity and symptoms
Gazyva has the potential to become a new standard of care for people living with systemic lupus erythematosus (SLE)
If approved, Gazyva would be the first Type II anti-CD20 therapy for SLE to directly target B cells, a key driver of inflammation and disease activity
SLE is a potentially life-threatening autoimmune disease that affects more than three million people worldwide

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO,

New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Genentech’s Gazyva Significantly Reduces Disease Activity in the Most Common Form of Lupus

Fri, 06 Mar 2026 08:45:00 -0400

Over three quarters of people on Gazyva plus standard therapy achieved at least a four-point improvement in SRI-4, a measure that assesses disease severity and symptoms
Gazyva has the potential to become a new standard of care for people living with systemic lupus erythematosus (SLE)
If approved, Gazyva would be the first Type II anti-CD20 therapy for SLE to directly target B cells, a key driver of inflammation and disease activity
SLE is a potentially life-threatening autoimmune disease that affects more than three million people worldwide

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO,